Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.
about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Is personalized medicine achievable in obstetrics?Short-term tocolytics for preterm delivery - current perspectivesA review of physiological and behavioral changes during pregnancy and lactation: potential exposure factors and data gaps.Relationships of chemical concentrations in maternal and cord blood: a review of available data.Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsAn assessment of dioxin exposure across gestation and lactation using a PBPK model and new data from Seveso.Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelDrug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?Designing drug trials: considerations for pregnant women.HILIC-MS-based shotgun metabolomic profiling of maternal urine at 9-23 weeks of gestation - establishing the baseline changes in the maternal metabolome.Coronary artery manifestations of fibromuscular dysplasia.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.Quantitative global sensitivity analysis of a biologically based dose-response pregnancy model for the thyroid endocrine system.Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in PregnancyPopulation approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Special population considerations and regulatory affairs for clinical researchMaraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.The future of physiologically based pharmacokinetic modeling to predict drug exposure in pregnant women.Distribution and biomarker of carbon-14 labeled fullerene C60 ([(14) C(U)]C60 ) in pregnant and lactating rats and their offspring after maternal intravenous exposureUpdate in fetal anesthesia for the ex utero intrapartum treatment (EXIT) procedureA simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancyOxytocin in pregnancy and the postpartum: relations to labor and its management.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure.Prediction of drug disposition on the basis of its chemical structure.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Roles of the circulating renin-angiotensin-aldosterone system in human pregnancy.Regulation of drug transporter expression and function in the placenta.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.
P2860
Q26741187-E5A077BB-E587-42FB-AB8F-B515629EC822Q26864177-6CB92947-F4BC-4091-8704-E48F5DF3F8CEQ26995337-66C67C60-1382-482C-8641-577D0FCFDBB0Q30733648-19952826-C33B-4356-8F5C-12D17C18F7E4Q30805001-F9B650D2-FF07-4238-8B33-3799B59CD5C5Q30828459-90C033D1-51EB-42FC-A875-38A0817EC8F0Q31068651-88F18358-2714-4670-9434-91D8127504EFQ33564516-4451AF62-3E73-4B57-AA9B-421EBED5F837Q33574126-43FF833B-8581-4D7B-B041-339978166A00Q34323195-ED512D4A-0A98-474C-9B15-E5847B022FC3Q34999905-AAFD2A9E-19F2-491B-A25F-A80298BEED74Q35181812-25194EE3-FDB8-40CE-B21D-CAF6168F294CQ35208027-E7A68E4A-0AC3-43AB-A8B3-207B357BEB58Q35211432-5D6C6BAD-DC55-4BBE-8F5A-232BB254F19FQ35600241-B8ABE901-07FC-4417-893A-01DA0C77C2C6Q35650275-57F9008F-5219-4D4D-A0DF-83F0607B8397Q35797203-15AC284D-22DE-482C-824D-1469B3BC7D3FQ35960706-6ECF51FE-B440-4434-885D-803E3138C7ADQ36078698-C00684F0-EF61-4237-BEC8-484BDAFCFAEDQ36187641-14526D1E-E7D4-4254-A236-974E33A7BC85Q36243626-3FC870F4-D4DE-4A32-A1D2-88E58F4AA5F0Q36390289-FB95007C-065C-4740-B141-676FF3D0CB86Q36599597-78F0EBA3-8967-4D4B-9D34-38C40793588EQ36625649-01D65603-C181-4174-88A6-AC85832FAB34Q36706781-0EE71CC3-7BD0-478B-8DFC-6E84DFC46829Q36712344-5670E7DC-9D02-426E-9EF0-CBB835C59A0BQ36717181-265D7337-7B6B-45B7-81C6-47D22B07FF46Q36727919-CBB12AD0-FE91-4D70-BBD0-0A6BBE156191Q36737498-016EA666-E91C-463F-9AE2-C33DD3A772D8Q37042135-407EE74C-AB17-44C7-BA2E-4D92D213D772Q37130110-AD78A1D6-5E4D-4F4D-AC24-C2A4D5E85857Q37207844-6D19FC24-DDBD-4CCE-BAF2-AE82E5EEB367Q37518418-49D44DBC-9C45-4BEE-A5E8-17383F144929Q38014312-1AEE90C4-45FB-4B23-A19C-69B6981235C5Q38044958-228D3471-D07B-419C-8B4C-603D00C7EF38Q38086778-4D2B9E09-6476-4D67-AB11-C9342F4BCDEAQ38087695-7E7AC0B9-BAFC-473D-ACC3-51FBE041F99AQ38148742-E956C0B1-AA8F-4EC9-865F-5C4A3C453BC9Q38323562-998214D5-50E5-460F-9439-B75AE6CA364EQ38420688-B7081083-BC6A-4B6B-881A-DDD6D4177564
P2860
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@en
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@nl
type
label
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@en
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@nl
prefLabel
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@en
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@nl
P2093
P2860
P1476
Anatomical, physiological and ...... sed pharmacokinetic modelling.
@en
P2093
Amin Rostami-Hodjegan
Khaled Abduljalil
Penny Furness
Trevor N Johnson
P2860
P304
P356
10.2165/11597440-000000000-00000
P50
P577
2012-06-01T00:00:00Z
P5875
P6179
1014084142